Home » Newsletters » BioWorld Science

BioWorld Science

July 16, 2012

View Archived Issues

Researchers at Lycera prepare new F1F0 ATPase inhibitors

Bristol-Myers Squibb patents new agents for HIV infection

Japanese team discloses novel treatments for diabetes

New EFNA modulators designed by Stem CentRx

New fusion protein from Bristol-Myers Squibb demonstrates antidiabetic activity

Bracco designs novel vaccines for allergy

New D3/5-HT2A receptor modulators patented by Roche

Belgian group discloses novel treatments for neurodegenerative disorders

NPS-1034 shows promise in EGFR-mutant cancer models

Grifols invests in biotechnology firm

CHF-5074 is well tolerated in patients with mild cognitive impairment

GlobeImmune patents novel vaccines for Ad-36 infection and obesity

Alnylam and Ascletis enter collaboration

GlaxoSmithKline withdraws supplemental NDA for Tykerb

Intranasal CP-024 leads to IGF-I induction in healthy volunteers

SEMA7A may have potential as a therapeutic target in breast cancer

Neupro launched in U.S. for Parkinson's disease and RLS

GSK and Theravance file applications for combination COPD candidate

Topline results expected early from phase IIb study of vigabatrin

Tissue Therapies obtains CE Mark for VitroGro ECM wound care product

OncoGenex provides update on phase III development of anticancer candidate

Supernus clarifies tentative approval conditions for Trokendi XR

In vivo results for ARRY-981 presented

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...